[Minimally invasive treatment of obesity with the intragastric balloon: a review].
Obesity is currently one of the most important problems in public health because of its prevalence and potential complications. The National Institute of Health (NIH) recommends to decrease body weight by about 10% because this initial weight loss can significantly decrease the severity of obesity-associated risk factors. The intragastric balloon (IB) was developed as a temporary aid to obtain such a weight loss and to induce a modification of eating habits. Results are encouraging in terms of weight loss, and improvement of co-morbidity. The best results have been obtained in patients with a body mass index (weight/size2) comprised between 30 and 40 kg/m 2, but superobese patients may also be good candidates for IB therapy before bariatric surgery. Overall complications are estimated to develop in about 3% of cases.